SCHEMBL4873872

SCHEMBL4873872

COc1ccc(S(N)(=O)=O)c(OCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
MAOB P27338 1/20 0.51
HDAC8 Q9BY41 1/20 0.50
ABCB1 P08183 3/20 0.48
HTR1A P08908 1/20 0.48
DRD2 P14416 1/20 0.48
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
PTGES2 Q9H7Z7 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6616903 0.94 AGXT (0.49) CA12CA1CA2CA4CA5A
SCHEMBL29965415 0.83 NPC1 (0.54) CA12CA1CA2CA4CA5A
SCHEMBL1013565 0.79 CA1 (0.56) CA12CA1CA2CA4CA5A
SCHEMBL29551296 0.78 PKM (0.55) CA12CA1CA2CA7CA9
SCHEMBL2183386 0.78 PKM (0.55) CA12CA1CA2CA7CA9
SCHEMBL23531819 0.78 ABCB1 (0.45) ABCB1PTGES2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL29764182 0.78 ABCB1 (0.45) ABCB1PTGES2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL8163340 0.78 MAOB (0.58) MAOBHDAC8ABCB1HTR1ADRD2
SCHEMBL7390468 0.78 MAOB (0.58) MAOBHDAC8ABCB1HTR1ADRD2
SCHEMBL31525501 0.78 MAOB (0.58) MAOBHDAC8ABCB1HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419967-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-02 US disclosed
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
EP-1086076-B1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2004-12-22 EP disclosed
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease HALE MICHAEL ROBIN (US) 2004-05-20 US disclosed
US-6613743-B2 Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-02 US disclosed
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-04-25 US disclosed
EP-1086076-A1 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-03-28 EP disclosed
WO-1999065870-A2 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097594-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP CA12 397/4885CA1 394/4885CA2 409/4885
US-20060172936-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP CA12 397/4885CA1 394/4885CA2 409/4885
US-20020049201-A1 Sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP CA12 397/4885CA1 394/4885CA2 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.